Company research
ORAGENICS INC
CIK 1174940Updated Sep 24, 2026
SecurityOGEN · NYSE_AMERICAN · equity
OGEN price & chart
Loading TradingView…
AMEX:OGEN on TradingView ↗About the company
We are a development-stage company dedicated to the research and development of nasal delivery pharmaceutical medications in neurology. Our lead product, the ONP-002 drug, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and it has been shown in animal models that it can cross the blood-brain barrier rapidly to reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
In the news
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21 ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other Events
Items 3.01, 8.01, 9.01
10-Q filing
Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 1.01, 5.02, 5.07, 9.01
DEFA14A filing
Show 5 more recent filings
DEF 14A filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
PRE 14A filing
10-Q filing
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 10,067,764Source | 1,472,510Source | 4,966,335Source | 14,758,025Source |
| Property, Plant and Equipment, NetUSD | — | — | 0Source | 121,062Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,399,726Source | 864,840Source | 3,483,501Source | 11,426,785Source |
| Assets, CurrentUSD | 10,067,764Source | 1,472,510Source | 3,865,774Source | 14,289,523Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,614,956Source | 607,670Source | 382,273Source | 2,862,738Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 9,811Source | 347,440Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,786,359Source | 1,684,395Source | — | — |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | 1,592,723Source | 1,592,723Source |
| Common Stock, Value, IssuedUSD | 4,271Source | 12,570Source | 3,081Source | 2,025Source |
| Additional Paid in CapitalUSD | 234,905,793Source | 216,561,717Source | 207,790,604Source | 196,977,071Source |
| Retained Earnings (Accumulated Deficit)USD | -226,628,659Source | -216,786,172Source | -206,218,254Source | -185,562,517Source |
| Stockholders' Equity Attributable to ParentUSD | 8,281,405Source | -211,885Source | 3,168,154Source | 13,009,302Source |
| Liabilities and EquityUSD | 10,067,764Source | 1,472,510Source | 4,966,335Source | 14,758,025Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | — | — | 1,798,181Source | 1,596,284Source |
| Operating Lease, Liability, CurrentUSD | — | — | 9,811Source | 204,447Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | 152,439Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | 202,834Source | 222,739Source | 812,861Source |
| Short-term InvestmentsUSD | 4,000,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 642,364Source | 516,049Source | 1,016,828Source | 742,203Source |
| Deferred Income Tax Expense (Benefit)USD | — | -1,408,287Source | -5,791,558Source | 3,714,988Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -9,246,387Source | -8,597,382Source | -7,290,880Source | -15,228,483Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | -936,284Source | -115,519Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | 127,519Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 16,781,273Source | 5,978,721Source | 283,880Source | -494,916Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 7,534,886Source | -2,618,661Source | -7,943,284Source | -15,838,918Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 22,353Source | 29,828Source | 3,347Source | 9,290Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 555,747Source | 516,049Source | 550,082Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | 771,437Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -13,193Source | -25,172Source | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | 22,443Source | — |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | 52,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | -29,956Source | 10,964Source |
| General and Administrative ExpenseUSD | 6,969,845Source | 6,444,381Source | 5,451,952Source | 4,474,465Source |
| Income Tax Expense (Benefit)USD | -136,910Source | — | — | — |
| InterestExpenseNonoperatingUSD | 785,930Source | 29,828Source | — | — |
| Investment Income, InterestUSD | 182,229Source | 45,897Source | 210,394Source | 135,900Source |
| Net Income (Loss) Attributable to ParentUSD | -9,842,487Source | -10,567,918Source | -20,655,737Source | -14,288,389Source |
| Nonoperating Income (Expense)USD | -616,894Source | -9,103Source | 249,166Source | 127,239Source |
| Operating ExpensesUSD | 9,362,503Source | 10,558,815Source | 20,942,556Source | 14,547,149Source |
| Other Nonoperating Income (Expense)USD | — | — | 69,363Source | 11,582Source |
| Proceeds from Issuance of Common StockUSD | 2,634,190Source | — | — | 69,289Source |
| Proceeds from Issuance of Long-term DebtUSD | 2,200,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | 37,653Source | 131,521Source |
| Operating Income (Loss)USD | -9,362,503Source | -10,558,815Source | -20,904,903Source | -14,415,628Source |
| Other Nonoperating Income (Expense)USD | — | — | 69,363Source | 11,582Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -9,979,397Source | -10,567,918Source | -20,655,737Source | -14,288,389Source |
| Income Tax Expense (Benefit)USD | -136,910Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -9,842,487Source | -10,567,918Source | -20,655,737Source | -14,288,389Source |
| Earnings Per Share, BasicUSD per share | -4.56Source | -1.6Source | -9.18Source | -7.11Source |
| Earnings Per Share, DilutedUSD per share | -4.56Source | -1.6Source | -9.18Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 2,157,076Source | 6,621,934Source | 2,249,694Source | 2,009,234Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 2,157,076Source | 6,621,934Source | 2,249,694Source | — |
| Interest Expense (non-operating)USD | 785,930Source | 29,828Source | — | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 27,391Source | 44,667Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -13,193Source | -25,172Source | — | — |
| General and Administrative ExpenseUSD | 6,969,845Source | 6,444,381Source | 5,451,952Source | 4,474,465Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -9,999,086Source | — | — | — |
| Interest ExpenseUSD | — | — | 30,591Source | 15,103Source |
| Investment Income, InterestUSD | 182,229Source | 45,897Source | 210,394Source | 135,900Source |
| Nonoperating Income (Expense)USD | -616,894Source | -9,103Source | 249,166Source | 127,239Source |
| Operating ExpensesUSD | 9,362,503Source | 10,558,815Source | 20,942,556Source | 14,547,149Source |
| Research and Development ExpenseUSD | 2,392,658Source | 4,114,434Source | 15,490,604Source | 10,072,684Source |
Offerings
Registration 333-288225
Registration 333-283927
Filing attachments
ex99-2.htm · 8-K · 2026-09-16
EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment ● James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies session at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026 ● Presentation is expected to address development and clinical…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-28
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update SARASOTA, Fla. - August 28, 2026 - Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical trial, U.S. regulatory pathway, and NYSE American continued listing status. Clinical & Reg…
Read attachment ↗ex99-2.htm · 8-K · 2026-05-19
EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 ORAGENICS PROVIDES INVESTOR UPDATE A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL - May 18, 2026 - Oragenics, Inc. (NYSE American: OGEN) Dear Fellow Shareholders, Since our last investor update, Oragenics has continued to execute across all fronts - in the clinic, in the regulatory pipeline, on our balance sheet, and strategically. We have reached a pivotal moment: our Phase IIa clinical trial of ONP-002 is active in Australia, patients…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-07
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and San Diego, CA - May 7, 2026 - Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a clinical-stag…
Read attachment ↗